USSN 10/802,540 Page 2

44. (newly added) The composition of claim 43, wherein the interferon -beta-la fusion protein comprises a portion of an immunoglobulin molecule.

- 45. **(newly added)** A physiologically active interferon-beta composition comprising a physiologically active interferon-beta-1a comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-40, coupled to a polymer comprising a polyalkylene glycol moiety, wherein the interferon -beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is an N- terminal end, wherein the physiologically active interferon -beta 1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta-1a in the physiologically active interferon -beta composition has an activity at least 2-fold greater relative to physiologically active interferon-beta-1b, when measured by an antiviral assay.
- 46. (newly added) The composition of claim 45, wherein the interferon-beta-1a is coupled to the polymer at a site by way of a glycan moiety of the interferon-beta-1a.
- 47. (newly added) The composition of claim 45, wherein the interferon-beta-1a is an interferon-beta-1a fusion protein.
- 48. (newly added) The composition of claim 47, wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.
- 49. **(newly added)** A physiologically active interferon-beta composition comprising a physiologically active glycosylated interferon-beta-1a comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27-40, N-terminally coupled to a polymer comprising a polyalkylene glycol moiety, wherein the physiologically active interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta 1a in the physiologically active interferon-beta composition has equal activity relative to physiologically active interferon-beta lacking said moiety, when measured by an antiviral assay.
- 50. (newly added) The composition of claim 49, wherein the interferon-beta is coupled to the polymer at a site by way of a glycan moiety on the interferon-beta.
- 51. (newly added) The composition of claim 49, wherein the interferon-beta-la is an interferon beta fusion protein.
- 52. (newly added) The composition of claim 51, wherein the interferon beta fusion protein comprises a portion of an immunoglobulin molecule.
- 53. (newly added) A stable, aqueously soluble, conjugated interferon-beta-la complex comprising a interferon-beta-la comprising an amino acid sequence selected from the group consisting of SEQ

Sec. 3. 4